A pharmaceutical composition for induction therapy which has a hypomethylating agent and a histone deacetylase inhibitor ("HDAC inhibitor")

The invention relates to methods for treating alopecia, e.g. androgenic alopecia, with an HDAC4 inhibitor, or a pharmaceutically acceptable salt or composition thereof.

ABSTRACT - 594669 Disclosed herein is a pharmaceutical composition for oral administration in capsule form comprising suberoylanilide hydroxamic acid or a pharmaceutically acceptable salt or hydrate thereof as an active ingredient in powder form, wherein about 100 mg of the active ingredient has an in vitro dissolution profile with a similarity factor (f2) of at least 56 to 100 compared to the reference dissolution profile of 52.7% dissolved at 10 minutes, 61.7% dissolved at 15 minutes, 67.7% di...

Disclosed is a crystalline form VI of vorinostat (also known as N-hydroxy-N'-phenyl-octanediamide or suberoylanilide hydroxamic acid (SAHA)), characterised by an XRPD spectrum comprising fourteen or more of the following degrees 2[theta] peaks: 5.01, 7.50, 9.23, 9.92, 10.51, 12.46, 14.90, 17.32, 19.35, 19.86, 22.36, 23.85, 24.20, 24.74, 25.81, 26.93, 27.85 plus or minus 0.2 degrees 2[theta]. Also disclosed is a process for the preparation of crystalline vorinostat form III, comprising: (a) mixin...

Disclosed is a process for the preparation of vorinostat (also known as N-hydroxy-N'-phenyl-octanediamide or suberoylanilide hydroxamic acid (SAHA)), comprising: (a) reacting suberic acid with aniline, or a salt thereof, to form suberanilic acid

Provided herein are methods for treating multiple myeloma by administering canfosfamide or a pharmaceutically acceptable salt thereof as a monotherapy, and also by administering canfosfamide or a pharmaceutically acceptable salt thereof as part of novel 5 combination therapies further comprising one or more of bortezomib, lenalidomide, vorinostat, carfilzomib, pomalidomide, and clotuzumab. SVCA_871690.1 19

Provided herein are methods for treating multiple myeloma by administering canfosfamide or a pharmaceutically acceptable salt thereof as a monotherapy, and also by administering canfosfamide or a pharmaceutically acceptable salt thereof as part of novel combination therapies further comprising one or more of bortezomib, lenalidomide, vorinostat, carfilzomib, pomalidomide, and elotuzumab.

Provided herein are methods for treating multiple myeloma by administering canfosfamide or a pharmaceutically acceptable salt thereof as a monotherapy, and also by administering canfosfamide or a pharmaceutically acceptable salt thereof as part of novel combination therapies further comprising one or more of bortezomib, lenalidomide, vorinostat, carfilzomib, pomalidomide, and elotuzumab.